chr15-48488379-C-G
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 4P and 4B. PM1PP2PP3BS2
The NM_000138.5(FBN1):c.3197G>C(p.Arg1066Thr) variant causes a missense change. The variant allele was found at a frequency of 0.000183 in 1,614,134 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000591 AC: 9AN: 152244Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251492Hom.: 0 AF XY: 0.0000441 AC XY: 6AN XY: 135920
GnomAD4 exome AF: 0.000196 AC: 287AN: 1461890Hom.: 1 Cov.: 33 AF XY: 0.000183 AC XY: 133AN XY: 727246
GnomAD4 genome AF: 0.0000591 AC: 9AN: 152244Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74386
ClinVar
Submissions by phenotype
not specified Uncertain:2
Variant summary: FBN1 c.3197G>C (p.Arg1066Thr) results in a non-conservative amino acid change located in the EGF like domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-05 in 251492 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in FBN1 causing Marfan Syndrome (4e-05 vs 0.00011), allowing no conclusion about variant significance. c.3197G>C has been reported in the literature in an individual affected with FBN1-related disease (example: Baudhuin_2015). These report(s) do not provide unequivocal conclusions about association of the variant with Marfan Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 25652356, 32123317). Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
The FBN1 c.3197G>C; p.Arg1066Thr variant (rs376659156), to our knowledge, is not described in the medical literature but contains an entry in ClinVar (Variation ID: 263470). It is observed in the general population at an overall frequency of 0.0039% (11/282908 alleles) in the Genome Aggregation Database. The arginine at codon 1066 is highly conserved, but computational algorithms (PolyPhen-2: possibly damaging, SIFT: tolerated) are inconclusive on the effect of this variant on protein structure/function. Due to the lack of clinical and functional data regarding this variant, its clinical significance cannot be determined with certainty. -
Familial thoracic aortic aneurysm and aortic dissection Uncertain:2
This missense variant replaces arginine with threonine at codon 1066 of the FBN1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in one individual suspected of having Marfan syndrome (PMID: 25652356). This variant has been identified in 11/282908 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.R1066T variant (also known as c.3197G>C), located in coding exon 25 of the FBN1 gene, results from a G to C substitution at nucleotide position 3197. The arginine at codon 1066 is replaced by threonine, an amino acid with similar properties. In a study of FBN1 clinical genetic testing among consecutive patients referred for Marfan syndrome, this alteration was reported in one patient with skeletal features (Baudhuin LM et al. J Hum Genet. 2015;60(5):241-52). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Marfan syndrome Uncertain:1
This missense variant replaces arginine with threonine at codon 1066 of the FBN1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in one individual suspected of having Marfan syndrome (PMID: 25652356). This variant has been identified in 11/282908 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not provided Uncertain:1
Reported as a variant of uncertain significance in patients with Marfan syndrome or an FBN1-related phenotype in published literature (PMID: 25652356, 32123317); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Although located in a calcium-binding EGF-like domain of the FBN1 gene, it does not affect a cysteine residue within this domain; cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (PMID: 12938084); This variant is associated with the following publications: (PMID: 32123317, 34663891, 12938084, 25652356) -
FBN1-related disorder Uncertain:1
The FBN1 c.3197G>C variant is predicted to result in the amino acid substitution p.Arg1066Thr. This variant was reported in an individual suspected of Marfan syndrome and referred for FBN1 testing (Baudhuin et al. 2015. PubMed ID: 25652356). Blood RNA analysis showed that this variant does not affect normal splicing (Table S1, Wai et al. 2020. PubMed ID: 32123317). This variant is reported in 0.0077% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Uncertain:1
This sequence change replaces arginine, which is basic and polar, with threonine, which is neutral and polar, at codon 1066 of the FBN1 protein (p.Arg1066Thr). This variant is present in population databases (rs376659156, gnomAD 0.008%). This missense change has been observed in individual(s) with FBN1-related disease (PMID: 25652356). ClinVar contains an entry for this variant (Variation ID: 263470). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt FBN1 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Marfan syndrome;C0265287:Acromicric dysplasia;C1858556:MASS syndrome;C1861456:Stiff skin syndrome;C1869115:Weill-Marchesani syndrome 2, dominant;C3280054:Geleophysic dysplasia 2;C3541518:Ectopia lentis 1, isolated, autosomal dominant;C4310796:Progeroid and marfanoid aspect-lipodystrophy syndrome Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at